Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00971256 | Urine Cytology and Utility in Bladder Recurrence | completed | — | 10 | Corewell Health EastOTHER | 0 | Nov 23, 2011 | clinicaltrials |
| NCT00622973 | USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases | completed | Phase 3 | 130 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Oct 12, 2011 | clinicaltrials |
| NCT01149174 |
| Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer(EMDA/PRE-TUR) |
| completed |
| Phase 3 |
| 352 |
| University of Rome Tor VergataOTHER |
| 1 |
| Oct 4, 2011 |
| clinicaltrials |
| NCT00335491 | Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors | completed | N/A | 49 | University of UtahOTHER | 1 | Sep 30, 2011 | clinicaltrials |
| NCT01442519 | Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer(BCG/EMDA-MMC) | completed | Phase 3 | 212 | University of Rome Tor VergataOTHER | 1 | Sep 28, 2011 | clinicaltrials |
| NCT01215266 | Sorafenib in Urothelium Cancer of Bladder | terminated | Phase 2 | 98 | Association of Urologic Oncology (AUO)OTHER | 0 | Sep 8, 2011 | clinicaltrials |
| NCT01087268 | Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer | unknown | Phase 3 | 75 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 15, 2011 | clinicaltrials |
| NCT00633204 | Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer | unknown | Phase 2 | 150 | Iwate Medical UniversityOTHER | 1 | Jun 23, 2011 | clinicaltrials |
| NCT00792025 | Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer | completed | Phase 2 | 80 | Institut CurieOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT01196403 | Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer | unknown | Phase 2 | 92 | Wales Cancer Trials UnitOTHER | 1 | Apr 1, 2011 | clinicaltrials |
| NCT00186277 | Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Mar 30, 2011 | clinicaltrials |
| NCT01082510 | Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study) | unknown | Phase 3 | 288 | Urological Oncology Council of Northern TokyoOTHER | 1 | Mar 24, 2011 | clinicaltrials |
| NCT00859768 | The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients | completed | N/A | 568 | Netherlands Open UniversityOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT00330707 | Combined Use of BCG and Interferon Alpha in Bladder Cancer | completed | Phase 2 / Phase 3 | 140 | National University Hospital, SingaporeOTHER | 1 | Mar 4, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
| NCT01264744 | Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test) | completed | — | 174 | Applied Spectral Imaging Ltd.INDUSTRY | 1 | Dec 23, 2010 | clinicaltrials |
| NCT00635336 | Novel Peptide Vaccination for Patients With Advanced Bladder Cancer | completed | Phase 1 | 20 | Iwate Medical UniversityOTHER | 1 | Oct 21, 2010 | clinicaltrials |
| NCT00962052 | Biomarker Discovery and Application in Bladder Cancer | unknown | — | 250 | Wolfson Medical CenterOTHER_GOV | 1 | Sep 14, 2010 | clinicaltrials |
| NCT00648102 | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer(CDX1307-02) | completed | Phase 1 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2010 | clinicaltrials |
| NCT00709462 | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) | completed | Phase 1 | 48 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2010 | clinicaltrials |
| NCT00101608 | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 15 | Mar 2, 2010 | clinicaltrials |
| NCT00782587 | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer(IPOP) | completed | Phase 1 | 14 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 8, 2010 | clinicaltrials |
| NCT00891748 | Safety Study on AdCD40L Gene Therapy for Bladder Cancer | completed | Phase 1 / Phase 2 | 12 | Uppsala UniversityOTHER | 1 | Jan 18, 2010 | clinicaltrials |
| NCT00315237 | Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract | completed | Phase 3 | 364 | Pierre Fabre MedicamentINDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00191477 | Instillation of Gemcitabine in Patients With Superficial Bladder Cancer | terminated | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2009 | clinicaltrials |
| NCT01000129 | Adaptive Planning in Bladder Cancer(APPLY) | unknown | Phase 2 | 32 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 22, 2009 | clinicaltrials |
| NCT00465725 | A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | completed | Phase 1 | 18 | Poniard PharmaceuticalsINDUSTRY | 1 | Sep 24, 2009 | clinicaltrials |
| NCT00077688 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 44 | Achieve Life SciencesINDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00867620 | Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma | unknown | — | 82 | National Taiwan University HospitalOTHER | 0 | Mar 24, 2009 | clinicaltrials |
| NCT00126958 | Cost-Effectiveness in Bladder Cancer | unknown | — | 500 | Erasmus Medical CenterOTHER | 0 | Feb 19, 2009 | clinicaltrials |
| NCT00816075 | Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection | unknown | Phase 2 / Phase 3 | 40 | Bozyaka Training and Research HospitalOTHER | 1 | Feb 17, 2009 | clinicaltrials |
| NCT00818350 | Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer | unknown | Phase 1 / Phase 2 | 25 | Campania Younger Oncologists AssociationOTHER | 0 | Jan 7, 2009 | clinicaltrials |
| NCT00491296 | Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia | unknown | — | — | HaEmek Medical Center, IsraelOTHER | 1 | Nov 7, 2008 | clinicaltrials |
| NCT00246974 | Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT | completed | Phase 2 | 125 | AstraZenecaINDUSTRY | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00109655 | Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure | unknown | Phase 1 | 75 | Cell GenesysINDUSTRY | 2 | Oct 3, 2008 | clinicaltrials |
| NCT00006118 | Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer | unknown | Phase 2 | — | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 2 | Jul 24, 2008 | clinicaltrials |
| NCT00696579 | Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 64 | University Of PerugiaOTHER | 1 | Jun 12, 2008 | clinicaltrials |
| NCT00216814 | Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors | terminated | — | 220 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Apr 22, 2008 | clinicaltrials |
| NCT00249301 | A Study of MLN8054 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 63 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 1, 2008 | clinicaltrials |
| NCT00315653 | Survivin Urine mRNA Assay Risk of Bladder Cancer Study | completed | — | 600 | Fujirebio Diagnostics, Inc.INDUSTRY | 1 | Mar 14, 2008 | clinicaltrials |
| NCT00001381 | A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00393809 | Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 18 | Hebrew University of JerusalemOTHER | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00490880 | Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer | completed | Phase 2 | 2 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00491114 | Intravesical Chemotherapy Treatment of Superficial Bladder Cancer | completed | Phase 2 | 8 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00192049 | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | May 17, 2007 | clinicaltrials |
| NCT00191711 | Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00146276 | Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer | unknown | Phase 3 | 178 | Association of Urologic Oncology (AUO)OTHER | 1 | Sep 27, 2006 | clinicaltrials |
| NCT00343356 | Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder | completed | Phase 2 | 138 | LanZhou UniversityOTHER | 0 | Jun 22, 2006 | clinicaltrials |
| NCT00011518 | Bladder Cancer Case Control Study of Arsenic in Water | completed | — | 600 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Mar 23, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Nov 23, 2011source: clinicaltrials